US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Nexalin Technology, Inc. - Warrant
(NQ:
NXLIW
)
0.0138
UNCHANGED
Last Price
Updated: 3:18 PM EDT, Sep 19, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nexalin Technology, Inc. - Warrant
< Previous
1
2
3
4
Next >
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
September 25, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on September 9
August 25, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Appoints Highly Experienced Financial Leader Justin Van Fleet as CFO to Support Nexalin’s Next Phase of Growth and Strategic Initiatives
August 01, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on June 3
May 28, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging Data
May 13, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA Feedback
May 01, 2025
Company initiates formal regulatory engagement on trial design for Alzheimer’s, dementia, and MCI indications
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and Insomnia
April 24, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient Management
April 23, 2025
AI-Powered Platform Now Fully Operational to Support Data Capture, Remote Monitoring, and Virtual Treatment with HALO™
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled Devices
April 21, 2025
Proposed bipartisan legislation would expand Medicare reimbursement pathways for AI-enabled medical devices — a framework that supports Nexalin’s Gen-3 HALO Clarity™ neurostimulation device integrated...
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use Disorders
April 14, 2025
Patent Approval Reinforces Nexalin’s Leadership in Non-Invasive Brain Stimulation for Addiction Treatment
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical Trial
April 02, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
March 26, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Receives Notice of Allowance from the USPTO for Patent Covering Deep Intracranial Frequency Stimulation (DIFS™) Technology for Opioid and Other Substance Use Disorders
March 03, 2025
Patent Strengthens Nexalin’s Intellectual Property Portfolio and Highlights the Potential of DIFS™ Technology in Addressing Substance Use Disorders, Including Opioids, Alcohol, Cocaine and...
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
February 28, 2025
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board
February 26, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
February 18, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition
February 10, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study
February 03, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session, Today, January 23
January 23, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology CEO Mark White Issues Letter to Shareholders Highlighting Recent Achievements and Outlook for 2025
January 14, 2025
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Completes Phase 1of its Innovative Virtual Clinic
December 23, 2024
AI Components for Electronic Data Capture and Patient Monitoring to be Integrated into Phase 2
From
Nexalin Technology, Inc.
Via
GlobeNewswire
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
November 26, 2024
Report Highlights Nexalin’s Unique Non-Invasive Solution Addressing Deep Brain Dysfunction, Positioned to Revolutionize Mental Health Treatment
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology CEO Provides Letter to Shareholders
November 11, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
November 01, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
November 01, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
October 28, 2024
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients
From
Nexalin Technology, Inc.
Via
GlobeNewswire
EXCLUSIVE: Nexalin Technology Says New Data Confirms Implantable Device Improves Cognitive Function, Restores Brain Activity in Alzheimer's Patients
↗
October 28, 2024
Nexalin says the study published in the Journal of Alzheimer's Disease shows DIFS may enhance cognition in mild Alzheimer's patients.
Via
Benzinga
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
October 22, 2024
From
Nexalin Technology, Inc.
Via
GlobeNewswire
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
October 17, 2024
Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment
From
Nexalin Technology, Inc.
Via
GlobeNewswire
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
↗
October 17, 2024
Nexalin Technology's clinical trial results highlight notable cognitive improvements in Alzheimer's patients using Deep Intracranial Frequency Stimulation technology. The study showed significant...
Via
Benzinga
< Previous
1
2
3
4
Next >
